
Loading, please wait...

Loading, please wait...

Recent research highlights that acromegaly-associated arthropathy remains a primary cause of long-term disability and reduced quality of life. This condition significantly affects the musculoskeletal health of patients, often persisting even after achieving biochemical control of growth hormone levels. A large-scale multicentre cross-sectional study in the UK recently examined the distribution and severity of this symptom, providing critical insights for clinical management.
The study involved 411 patients with a median age of 60 years. Findings showed that 82.5% of these individuals experienced chronic joint pain. Specifically, 43.3% of participants reported moderate pain, while 13.1% suffered from severe symptoms. The knees were the most frequently affected joints, impacting 54.7% of the cohort. Additionally, patients frequently reported pain in the lower back (47.7%), hips (38.9%), and shoulders (38.6%). These results suggest that the arthropathy is typically polyarticular and focuses on weight-bearing joints.
Managing the musculoskeletal complications of acromegaly requires a multidisciplinary approach. Consequently, over 60% of patients in the study utilized at least one type of analgesic to manage their symptoms. Furthermore, one-third of the participants required two or more classes of pain medication. Beyond oral therapies, 26.5% of patients underwent at least one joint injection. Surgical interventions were also common, with 17% of patients receiving a joint prosthesis at a median age of 59. Therefore, early identification and intervention for joint pain are vital to improving patient outcomes.
The knees are the most frequently affected site, followed by the lower back, hips, and shoulders. This pattern often mimics degenerative osteoarthritis but occurs at a younger age in acromegaly patients.
Management involves a combination of biochemical control of the underlying disease and symptomatic relief. Common treatments include oral analgesics, intra-articular injections, and in severe cases, joint replacement surgery.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.
References
1. Kyriakakis N et al. Distribution, Severity and Management of Joint Pain in Patients with Acromegaly. Eur J Endocrinol. 2026 Mar 05. doi: undefined. PMID: 41783995.
2. Miller A, et al. Management of arthropathy in acromegaly: A review of clinical practices. Journal of Endocrinological Investigation. 2023.
3. Wass JA, et al. The pathogenesis of acromegalic arthropathy. Oxford Textbook of Endocrinology. 2022.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A multicentre study of 411 patients reveals that over 80% of individuals with acromegaly suffer from significant, multi-site joint pain requiring analgesics...
7 months ago

A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today

A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today

This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday